



**Regent Pacific further invests up to GBP 3 million in
The Diabetic Boot Company Limited,
increasing its stake initially to 23.0% and potentially up to 33.1%**

- Funding to support the commercialisation of Diabetic Boot’s PulseFlowDF product globally; first sales to Veteran Administration, Medicare and Medicaid patients in the US expected this quarter
- PulseFlowDF boot is designed to treat diabetes related foot ulcer complications; the condition accounts for approximately 1.5 million amputations globally every year
- Type 2 Diabetes is one of the fastest growing chronic conditions, affecting approximately 415 million worldwide in 2015, and approximately 130 million in China, more than any other country in the world

(20 April 2016, Hong Kong) – Regent Pacific Group Limited (“**Regent Pacific**” or “**the Group**”; stock code: 00575), a healthcare and life sciences investment group, announces today that it has entered into an agreement with The Diabetic Boot Company Limited (“**Diabetic Boot**”) to subscribe for up to 130,434 new Diabetic Boot shares and up to 65,217 Fundraising Warrants for a consideration of up to approximately GBP 3 million (or approximately US\$4.2 million). The funding, which is part of Diabetic Boot’s broader plans to raise capital of up to GBP 3.5 million (or approximately US\$5 million), will be staged in three equal tranches and is expected to close before or on 31 December 2016, and is subject to and conditional upon Diabetic Boot shareholder approval and certain performance milestones being met.

Diabetic Boot, a private single product medical device company based near Oxford in the United Kingdom, is focused on the treatment of diabetic foot ulcers (“**DFUs**”). Its lead product PulseFlowDF, which has sales clearance in Europe and the US, combines intermittent plantar compression with the current standard of care for the treatment of DFUs called offloading. The boot is in full production in the UK and all outstanding orders have been shipped. Sales of PulseFlowDF to the Veterans Administration, Medicare and Medicaid patients in the US are expected to commence later this quarter. Distribution partners in Austria, Australia, Canada, Germany, Mexico and South America, Saudi Arabia, Switzerland and New Zealand have also been contracted.

Jamie Gibson, CEO of Regent Pacific said: “Diabetes is a fast growing and often devastating disease with the global prevalence estimated to be 9% among adults aged of 18+ years, and in China alone, an estimated 130 million suffer from the condition with a further 490 million at the pre-diabetes stage. Foot ulcers are a very serious complication of diabetes and one diabetic related amputation takes place in the world every 20 seconds. Our investment in Diabetic Boot underscores our confidence that this exciting and unique product can potentially improve the quality of life of hundreds of thousands of lives and play a role in reducing the financial burden on health authorities across the world by reducing the need for amputations.”

“This investment is firmly aligned with our strategy of seeking value-led investments in the healthcare and life sciences industry, particularly those with applications in Asian markets. By building a more



meaningful stake in Diabetic Boot ahead of full commercialization of its landmark product, we believe we can better protect and drive value of our existing significant investment in the company, and ultimately, deliver greater returns to our own shareholders over time.”

The funding, which will be paid across three equal tranches of approximately GBP 1 million (or approximately US\$1.4 million) and is expected to close before or on 31 December 2016, is subject to and conditional upon Diabetic Boot shareholder approval and certain performance and other milestones being met. For tranche two this includes sales of not less than US\$640,000 in the US; and for tranche three, cumulative sales in the US of not less than US\$1 million since incorporation, and approximately US\$142,770 of sales in the Rest of the World during calendar year 2016. Following completion of the first tranche, the Group will have the right to appoint two representatives as directors of Diabetic Boot. Upon completion of all three tranches, Regent Pacific’s shareholding in Diabetic Boot will increase from 16.8% percent to 33.1 %.

- END -

About Regent Pacific

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare and life sciences sectors. Its wholly-owned subsidiary, Plethora Solutions Holdings Plc, is a specialty pharmaceutical company whose core product PSD502[®] is the first EU approved topical prescription treatment for Premature Ejaculation, set to launch in EU in the latter half of 2016. The Group has a strong track record of investments and has returned US\$298 million to shareholders in the 17.5 years of financial reporting since its IPO.

For further information, please contact:

Finsbury

James Hill

t : 3166 9888

e : james.hill@finsbury.com

Karen Yu

t : 3166 9866

e : Karen.yu@finsbury.com